

Figure 2—Data from Fig. 1 treated according to Eq. 3 (A = 70).

The data treatment (3-6) of the curve is as follows. If the amount is n moles and if there are x moles decomposed at time t, then x is present as liquid. If the solubility of parent compound in the liquid is S moles of RCOOH/mole of RH, then the amount of solid present is n - x - Sx; the rate equation then is:

$$dx/dt = -k_s(n - X - Sx) - k_l Sx$$
 (Eq. 1)

where  $k_s$  and  $k_l$  are solid and liquid first-order rate constants, respectively. If the mole fraction X = x/n is used in place of moles decomposed, the equation becomes:

$$dX/dt = -k_s(1 - x - SX) - k_l SX$$
 (Eq. 2)

By integration:

$$\ln(1 + AX) = -\alpha t \tag{Eq. 3}$$

where  $A = \alpha/k_s$  and  $\alpha = k_l S - k_s S - k_s$ . The value of A is found by iteration, and linearization according to Eq. 3 is shown in Fig. 2. Once all solid has disappeared, the model no longer holds and simply reverts to solution kinetics as pointed out by Carstensen and Musa (3).

The values at four temperatures are shown in Table I. The least-squares fit for the Arrhenius plot (Fig. 3) is:

$$\ln k_s = (-38,650/R)(1/T) + 46.25$$
 (Eq. 4)

with a correlation coefficient of -0.992. The activation

Figure 3—Arrhenius data of decomposition rate constants, k<sub>s</sub>, of the parent compound in the solid state (Table I).

1000/T. °K-1

2.7

2.75

2.8

#### 124 / Journal of Pharmaceutical Sciences Vol. 69, No. 1, January 1980

2.65

n k<sub>s</sub>

Table I—Parameter Values at Different Temperatures

Temperature	1000/T	A <sup>a</sup>	$\alpha^b$ , hr <sup>-1</sup>	<i>k<sub>s</sub><sup>c</sup></i> , hr <sup>-1</sup>	ln k <sub>s</sub>
85°	2.792	28	0.0070	0.00025	-8.094
90° 95°	$2.754 \\ 2.716$	70 110	0.0594 0.116	$0.00085 \\ 0.00151$	-7.070 -6.496
101°	2.673	175	0.571	0.00327	-5.723

<sup>a</sup> The A denotes the iteration constant in Eq. 3. <sup>b</sup> The  $\alpha$  denotes the slope of the line according to Eq. 3. <sup>c</sup> The  $k_s$  is the solid-state decomposition constant.

energy for  $k_s$  is high compared to usual solution kinetics (although within range) but is lower than that for, for instance, the solid-state decomposition of substituted benzoic (3) or salicylic (6) acids. Solid-state activation energies are extremely high (3-7, 9-13). When they are wholly dictated by physical propagation (type I), the energy of activation supersedes the normal range for solution kinetics by a factor of two to three. Type II reactions usually have intermediate activation energies.

(1) R. A. Parker, T. Karyia, J. M. Grisar, and V. Petrow, J. Med. Chem., 20, 781 (1977).

(2) C. E. H. Bawn, in "Chemistry of the Solid State," W. E. Gardner, Ed., Butterworths Scientific Publication, London, England, 1955, p. 254.

(3) J. T. Carstensen and M. N. Musa, J. Pharm. Sci., 61, 112 (1972).

(4) J. T. Carstensen and P. Pothisiri, ibid., 64, 37 (1975).

(5) J. T. Carstensen, ibid., 63, 1 (1974).

- (6) P. Pothisiri and J. T. Carstensen, *ibid.*, 64, 1931 (1975).
- (7) S. Kornblum and B. Sciarrone, ibid., 53, 935 (1964).
- (8) R. R. A. Abou-Shaaban and A. P. Simonelli, Thermochim. Acta, 26, 67 (1978).
  - (9) *Ibid.*, **26**, 89 (1978).

(10) Ibid. 26, 111 (1978).

(11) R. R. A. Abou-Shaaban, J. A. Reffner, and A. P. Simonelli, Thermochim. Acta, 26, 125 (1978). (12) Ibid., 26, 137 (1978).

J. T. Carstensen x Rohit C. Kothari School of Pharmacy University of Wisconsin Madison, WI 53706

Received June 25, 1979.

Accepted for publication September 17, 1979.

The authors are indebted to Dr. R. A. Parker and Dr. M. A. Zoglio for valuable help and assistance.


# Structure-Activity Analysis of Hydrazide Monoamine Oxidase Inhibitors Using Molecular Connectivity

Keyphrases D Molecular connectivity analysis-hydrazide monoamine oxidase inhibitors, structure-activity relationships 🗆 Structure-activity relationships-hydrazide monoamine oxidase inhibitors, molecular connectivity analysis D Monoamine oxidase inhibitors-hydrazides, structure-activity relationships, molecular connectivity analysis

#### To the Editor:

Fulcrand et al. (1) recently analyzed a series of monoamine oxidase inhibitors and found good correlations between pI<sub>50</sub> values and electronic and steric parameters for 24 compounds. The methods of Hansch et al. (2) and Free and Wilson (3), as employed by Fulcrand *et al.* (1), were equally successful in correlating physical properties with

Table I—Hydrazide Monoamine Oxidase Inhibitors



Compound	$\mathbf{R}_{1}$	$R_2$	$\mathbf{R}_{3}$	$R_4$	$R_5$	R <sub>6</sub>	E	pI <sub>50</sub>
T	н	Н	Н	Н	Н	CH(CH <sub>3</sub> ) <sub>2</sub>	-0.4310	5.42
ц	Ĉl	H	H H	Н	н	$CH(CH_3)_2$	-0.4425	5.60
III	Ĥ	CI	н	н	н	$CH(CH_3)_2$	-0.4368	5.40
ÎŶ	Ĥ	Н	CI H	H H	н	$CH(CH_3)_2$	-0.4433	5.96
Ŷ	$\overline{C}H_3$	н	Ĥ	н	н	$CH(CH_3)_2$	-0.4390	5.54
VI	H	$CH_3$	Н	Н	H H	$CH(CH_3)_2$	-0.4333	5.05
VIĪ	н	Ĥ	$CH_3$	H H	н	$CH(CH_3)_2$	-0.4355	5.40
VIII	OCH <sub>3</sub>	н	Н	Н	н	$CH(CH_3)_2$	-0.4365	5.62
ĪX	H	OCH <sub>3</sub>	н	н	Н	$CH(CH_3)_2$	-0.4365	5.42
X	Н	H	OCH <sub>3</sub>	H H H H H	н	$CH(CH_3)_2$	-0.4353	5.52
XI	H	H H	н	Н	$CH_3$	$CH(CH_3)_2$	-0.4125	5.00
XII	Cl	н	H H	н	CH <sub>3</sub>	CH(CH <sub>3</sub> ) <sub>2</sub>	-0.4148	5.16
XIII	Н	Cl	н	н	$CH_3$	$CH(CH_3)_2$	-0.4118	4.96
XIV	H	н	Cl	Н	$CH_3$	CH(CH <sub>3</sub> ) <sub>2</sub>	-0.4155	5.00
XV	Н	Н	Н	$CH_3$	$CH_3$	$CH(CH_3)_2$	-0.4025	4.34
XVI	н	Н	H Cl	$CH_3$	$CH_3$	$CH(CH_3)_2$	-0.4133	4.80
XVII	н	$CH_3$	H H	Н	$CH_3$	$CH(CH_3)_2$	-0.4115	4.90
XVIII	H H	H H H	н	Н	н	$C_2H_5$	-0.4232	5.82
XIX	н	Н	Cl	H H	Н	$C_2H_5$	-0.4262	6.00
XX	H,	н	н	Н	н	$CH_2C_6H_5$	-0.4448	6.14
XXI	H H H	H H	Н	н	н	$CH(CH_3)C_6H_5$	-0.4340	5.70
XXII	Н	н	$CH_3$	н	Н	CH(CH <sub>3</sub> )C <sub>6</sub> H <sub>5</sub>	-0.4340	6.05
XXIII	Н	н	$OCH_3$	н	н	CH(CH <sub>3</sub> )C <sub>6</sub> H <sub>5</sub>	-0.4368	6.00
XXIV	Н	Н	Cl	Н	Н	$CH_2C_6H_5$	-0.4560	6.96

the activity of the molecules whose structures are shown in Table I. Electronic effects, reflected in polarographic half-wave potentials, and steric effects were the most important parameters examined in the correlations. It was concluded that the monoamine oxidase inhibitory activity of the series was due to the hydrazide group, which could form an unstable diazene with the monoamine oxidase flavine coenzyme before rearrangement to bind on the enzyme.

An alternative approach to determining structureactivity relationships and to improving the understanding of the mechanism of action of a series of compounds evolved from the work of Kier and Hall (4, 5) and has been used extensively in structure-activity analyses (6–8). This approach, the molecular connectivity method, has its roots in the topology of the molecules, from which a set of indexes may be calculated. These indexes encode molecular structural information into the regression analysis. The indexes may be used alone or in conjunction with other physical parameters to discover correlations concerning biological or chemical activity within a series of molecules.

Molecular connectivity indexes were calculated for the monoamine oxidase inhibitors of Fulcrand *et al.* (1). Linear regression analysis by computer search for the three variables that gave the best correlation with activity as monoamine oxidase inhibitors yielded:

$$pI_{50} = -5.2 - 29E - 0.82^{2}\chi + 1.8^{3}\chi_{\nu}^{\nu}$$
  

$$n = 24 \quad r = 0.941 \quad s = 0.201 \quad F = 52$$
(Eq. 1)

where E represents the half-wave potential; the other indexes calculated for the molecules were shown previously (4). This equation clearly indicates that electronic effects contribute to the monoamine oxidase inhibitor activity of the hydrazides, in agreement with Fulcrand *et al.* (1). The  $^{2}\chi$  index gives weight to structural features of two-bond lengths in the molecules, whereas the  $^{3}\chi^{\nu}_{p}$  index represents three-bond path lengths within the molecules and also emphasizes the importance of the heteroatoms in the substituents.

To gain further insight into structural influences on the interaction between the inhibitors and the active enzyme site, regression analyses were run on a subseries of molecules formed by the deletion of certain substituent groups. In particular, the nitrogen substituent ( $R_6$ ) was kept constant with the isopropyl group to determine if this substituent was governing the inhibitory potency. This subset of 17 molecules correlates with pI<sub>50</sub>:

$$pI_{50} = -4.1 + 0.59 {}^{0}\chi^{2} - 0.94 {}^{2}\chi - 23E$$

$$n = 17 \quad r = 0.951 \quad s = 0.134 \quad F = 41$$
(Eq. 2)

Again, E and  ${}^{2}\chi$  emerge as significant parameters, but  ${}^{3}\chi_{p}^{\nu}$  is replaced by  ${}^{0}\chi^{\nu}$ . However, this new valency chi index retains an indication of a contribution of heteroatoms in the substituents to activity. If the R<sub>4</sub> and R<sub>5</sub> substituents are limited to hydrogen while R<sub>6</sub> is kept as isopropyl, then only 10 molecules remain and the correlation is:

$$pI_{50} = -34 - 94E - 2.6 \,^{4}\chi^{\nu}_{pc}$$
  
n = 10 r = 0.923 s = 0.100 F = 20 (Eq. 3)

Electronic effects again contribute to the relationship. The  ${}^{4}\chi^{\nu}_{pc}$  index relates well to systems where ring substitutions have been made and indicates that monoamine oxidase inhibitor activity of the hydrazides is related to the ring in some fashion, perhaps indirectly through its effects on the neighboring ether linkage. A further argument can be made for this point if all substituents from R<sub>1</sub> through R<sub>5</sub> are restricted to hydrogen and R<sub>6</sub> is varied. Only four molecules remain in the set, but there is no hint of correlation with electronic or chi parameters to the monoamine oxidase inhibitor activity.

Although the  $R_6$  substituents certainly must affect the hydrazide, these observations would clearly argue against the hydrazide moiety as the sole contributor to biological activity. Therefore, it may be concluded that monoamine oxidase inhibitor activity of these hydrazides depends

Journal of Pharmaceutical Sciences / 125 Vol. 69, No. 1, January 1980

largely on the nature of the ring substitution as well as on the half-wave reduction potential of the ring, its substituents, or the ether oxygen.

(1) P. Fulcrand, G. Berge, A. Noel, P. Chevallet, J. Castel, and H. Orzalesi, Eur. J. Med. Chem., 13, 177 (1978).

(2) C. Hansch, R. M. Muir, T. Fujita, P. O. Maloney, F. Gerer, and M. Strejc, J. Am. Chem. Soc., 85, 2817 (1963).

(3) S. M. Free and J. R. Wilson, J. Med. Chem., 7, 395 (1964).

(4) L. B. Kier and L. H. Hall, "Molecular Connectivity in Chemistry and Drug Research," Academic, New York, N.Y, 1976.

(5) L. B. Kier and L. H. Hall, J. Med. Chem., 20, 1631 (1977).

(6) L. B. Kier and R. A. Glennon, Life Sci., 22, 1589 (1978).

(7) R. A. Glennon and L. B. Kier, Eur. J. Med. Chem., 13, 219 (1978).

(8) R. A. Glennon, L. B. Kier, and A. T. Shulgin, J. Pharm. Sci., 68, 906 (1979).

Alfred J. Richard × Lemont B. Kier Department of Pharmaceutical Chemistry Medical College of Virginia Virginia Commonwealth University Richmond, VA 23298

Received March 15, 1979.

Accepted for publication October 26, 1979.

## Calculation of Cutaneous Metabolic Rate Constant from Diffusion Model

Keyphrases □ Rotating disk—analysis, cutaneous metabolism of vidarabine, guinea pig, *in vitro* study □ Skin—metabolism of vidarabine, rotating-disk method, guinea pig, *in vitro* study □ Antiviral agents—vidarabine, cutaneous metabolism, rotating-disk method, guinea pig, *in vitro* study □ Vidarabine—cutaneous metabolism, analysis by rotating-disk method, guinea pig, *in vitro* study

### To the Editor:

A method for the determination of the cutaneous metabolic rate constant for vidarabine (I) from a rotating-disk diffusion model was reported recently by Leung and Ando (1). They calculated the enzyme rate constant from the observed flux using:

$$k_m = 1 / \left[ \frac{C_A(h)}{-F_A} - \frac{h}{D_{aqA}} \right] (m)$$
 (Eq. 1)

where  $k_m$  is the first-order enzyme rate constant,  $C_A(h)$ is the initial substrate concentration,  $F_A$  is the flux of the substrate in the system, h is the aqueous diffusion layer thickness,  $D_{aqA}$  is the aqueous diffusion coefficient, and m is the membrane thickness. Equation 1 was derived from Eq. 25 of a previous publication by Ando *et al.* (2) by taking the limit of  $\theta \to 0$  such that  $\tanh \theta \to \theta$ :

$$\frac{1}{r} = C_1 \tanh \kappa m \qquad (Eq. 2)$$

where:


$$\kappa = \sqrt{k_m/D_A}$$

$$C_1 = D_A \left[ \frac{C_A(h)}{-F_A} - \frac{h}{D_{aqA}} \right]$$

$$\theta = \kappa m$$

and  $D_A$  is the diffusion coefficient of the substrate for the cutaneous tissue.

126 / Journal of Pharmaceutical Sciences Vol. 69, No. 1, January 1980



**Figure 1**—Plot of flux versus substrate concentration. The slope of the linear regression line is  $3.11 \times 10^{-4}$  cm<sup>-2</sup> sec<sup>-1</sup> (r = 0.9997).

The  $k_m$  of the deaminase enzyme in guinea pig epidermis was calculated to be 0.156 sec<sup>-1</sup>, which contradicts the  $\theta \rightarrow 0$  assumption by giving  $\theta$  values of 0.25 and 24.9 for  $D_A$ values of  $1.0 \times 10^{-5}$  and  $1.0 \times 10^{-9}$  cm<sup>2</sup>/sec, respectively. Obviously, the validity of Eq. 1 is questionable when  $D_A$ is smaller than  $1.0 \times 10^{-5}$  cm<sup>2</sup>/sec. Strictly speaking, the  $\theta \rightarrow 0$  assumption should never be valid because it leads to either  $D_A \rightarrow \infty$ , *i.e.*, no diffusional barrier exists, or  $m \rightarrow 0$ , *i.e.*, no membrane exists, since  $k_m$  is finite. In neither case will the simultaneous diffusion and metabolism theory

Table I-Fluxes \* of I at Different Concentrations

Concentration,	Flux,	Mean Flux			
$\mu M$	%/cm <sup>2</sup> min	%/cm <sup>2</sup> min	$\mu M/cm^2$ sec		
0.25	1.630 1.956	1.826	$7.61 \times 10^{-5}$		
0.50	1.892 1.888 0.797	1.283	$1.07 \times 10^{-4}$		
0.75	1.164 1.662 1.713	1.679	$2.10  imes 10^{-4}$		
1.0	1.717 1.691 1.921	1.616	$2.69  imes 10^{-4}$		
6.0	1.230 1.568 1.787	1.839	$1.84 \times 10^{-3}$		
600.0	2.144 0.388 0.399 0.346	0.378	$3.78 \times 10^{-2}$		

<sup>a</sup> Negative signs for all flux values, which indicate directions of the fluxes, are omitted in this table.

0022-3549/80/0100-0126\$01.00/0 © 1980, American Pharmaceutical Association